Aptevo Therapeutics (APVO)
Nasdaq Market Closed
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy. The company develops engineered antibody-based drug candidates intended to redirect or enhance the immune system’s ability to recognise and destroy malignant cells. Its research strategy is built around modular protein technologies that can be used to design monospecific, bispecific, and multispecific molecules with tailored binding properties.
A central part of Aptevo’s approach is its ADAPTIR and ADAPTIR-FLEX platforms. These technologies are designed to produce therapeutic proteins that can engage immune-cell receptors, tumour-associated antigens, or other disease-relevant targets in a single construct. This structure may allow candidates to bring immune effector cells into closer contact with cancer cells or activate co-stimulatory pathways that support anti-tumour activity.
The company’s clinical programs include ALG.APV-527, a bispecific candidate designed to target a tumour antigen and a co-stimulatory receptor, and a CD3xCD123 program being evaluated as a potential treatment for acute myeloid leukaemia. CD123 is commonly investigated in blood cancers, while CD3 engagement is intended to recruit T cells to attack diseased cells. Aptevo also lists several preclinical candidates, including APVO711, APVO0442, and APVO603, that reflect the broader application of its platform.
As a listed stock, APVO represents exposure to an early-stage biotechnology company where investment performance is closely tied to clinical development milestones, partnership opportunities, intellectual property strength, capital needs, and the competitive landscape for next-generation immuno-oncology therapies.
Last updated
- Market Cap
- $5,757,005
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- -$8,767,995
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 2401 4TH AVE., SEATTLE, WA, 98121
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $5,757,005
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -$8,767,995
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.5
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.33
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -22.33
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -239.64%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -139.82%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.36
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 3.36
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 3.05
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $75,920
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 4.62
Income Statement
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 3.11M | 12.29M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | — | — | — | 3.11M | 12.29M |
| Operating income | -26.31M | -24.6M | -28.88M | -28.64M | -21.4M |
| EBITDA | -26.07M | -24.25M | -28.31M | -27.74M | -20.26M |
| Net income | -27.54M | -24.13M | -17.41M | 8.03M | -28.46M |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 26.31M | 24.6M | 28.88M | 31.76M | 33.69M |
| Basic EPS | -87.27 | -31,460.23 | -834,058.8 | 920,145.6 | -3,557,505.6 |
| Diluted EPS | -87.27 | -31,460.23 | -834,058.8 | 920,145.6 | -3,557,505.6 |
Balance Sheet
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Total assets | 27.19M | 15.59M | 24.84M | 34.22M | 56.6M |
| Total liabilities | 9.81M | 10.84M | 12.62M | 16.24M | 55.39M |
| Total equity | 17.38M | 4.76M | 12.22M | 17.97M | 1.22M |
| Cash & equivalents | 21.62M | 8.71M | 16.9M | 22.64M | 45.04M |
| Current assets | 23.08M | 10.66M | 19.07M | 27.45M | 51.31M |
| Current liabilities | 6.05M | 6.21M | 7.22M | 8.71M | 34.87M |
| Accounts payable | 877K | 1.24M | 3.98M | 3.5M | 3.46M |
| Receivables | 0 | 0 | 0 | 2.5M | 3.66M |
| Long-term debt | — | — | — | 1.46M | 3.71M |
Cash Flow
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Operating cash flow | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing cash flow | — | — | — | -29K | -713K |
| Financing cash flow | 38.5M | 15.6M | 6M | -2.62M | 26.16M |
| Change in cash | 12.91M | -8.19M | -5.73M | -23.67M | 3.77M |
| Net income | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aptevo Therapeutics Inc. | View Filing | |
| form 3 | Form 3 — NIOWAVE, INC. | View Filing | |
| form 3 | Form 3 — NIOWAVE, INC. | View Filing | |
| edgar index | 3 — Aptevo Therapeutics Inc. | View Filing | |
| form 3 | Form 3 — Janatpour Mary Jo | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 10-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | EFFECT — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | UPLOAD — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | CORRESP — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | S-1 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | DEF 14A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | PRE 14A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 424B4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | EFFECT — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | CORRESP — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| form 4 | Form 4 — Grant Grady III | View Filing | |
| edgar index | SCHEDULE 13G/A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 3 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| form 3 | Form 3 — BANK OF AMERICA CORP /DE/ | View Filing | |
| form 3 | Form 3 — BOFA SECURITIES, INC. | View Filing | |
| form 3 | Form 3 — BANK OF AMERICA NA | View Filing | |
| edgar index | S-1 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 8-K — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 10-Q — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 424B4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing | |
| edgar index | 4 — Aptevo Therapeutics Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free